Daniel Krizek has over 18 years of experience in biotechnology / pharmaceuticals and has spent the last 15 years as an investor, focusing on "tomorrow's cures" for today's critical medical needs. His investments encompass the entire lifecycle of biotech companies, from initial Series A funding through advanced venture rounds, cross-over, IPO, and a diverse array of public financings, including follow-ons, private investment in public equity, and reverse mergers. He has financed over 100 private biotech companies and participated on dozens of Boards as an observer.

Mr. Krizek currently serves as Portfolio Manager at Citadel / Surveyor Capital, where he manages one of the largest biotech investment portfolios in the world. Prior to Citadel, he served as Director at Bain Capital, where he managed private and public investments in biotech. Before Bain Capital, he worked as a consultant at McKinsey. Mr. Krizek received a BA from Stanford and holds CFA (Chartered Financial Analyst) and CAIA (Chartered Alternative Investment Analyst) designations.